Adoptive Cellular Therapy

"The efficacy and safety of adoptive cell therapy, specifically the use of CAR-T cells, in the treatment of many malignancies is accelerating its investigation into the application of this technology in other tumors."

DR. FELIPE PRÓSPER
SENIOR RESEARCHER. ADOPTIVE CELLULAR THERAPY RESEARCH GROUP

Home >
Research >
Research divisions >
Research programs >
Hemato-Oncology >
Adoptive Cell Therapy. Hemato-oncology

The Adoptive Cell Therapy Group is a multidisciplinary team of basic and clinical researchers focused on the identification of new tumor antigens as targets for CAR-T therapies, the development of optimized CARs, as well as the characterization of the molecular mechanisms involved in the responses to these treatments.

Adoptive cell therapy for cancer is a type of immunotherapy based on the use of agents that enhance patients' own immune cells to stimulate specific antitumor responses. The use of genetically modified T cells, and in particular chimeric antigen receptor T cells (CAR-T), is emerging as the most innovative and promising advanced therapy for the treatment of cancer for decades.

CAR-T therapies have demonstrated efficacy in certain hematological cancers such as B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, current treatments have not proven to be as effective for other tumor types such as multiple myeloma or acute myeloid leukemia.

Our group is linked to the Centro de Investigación Biomédica en la Red de Cáncer (CIBERONC) of the Instituto de Salud Carlos III (ISCIII), as well as to numerous national and international academic and research centers.

Need more information?

If you are interested in learning more about our research, please contact us.

Objectives of the Adoptive Cell Therapy
Research Group

Combining innovation and technology to design new effective therapies against hematological cancer

Improve CART cell-based therapeutic strategies by identifying specific antigens, developing optimized CARs, and evaluating their therapeutic efficacy.

To understand and characterize the molecular mechanisms involved in the efficacy and/or resistance to CART therapies, we employ a functional strategy combined with the use of multi-omics technologies, genetically modified animals and multiparametric flow cytometry.

NEW IMMUNOTHERAPIES

Design of new generation CAR-T therapies

In the treatment of multiple myeloma or acute myeloid leukemia there are still patients who are non-responders or partial responders and there is a significant relapse rate after complete remission. In our group we are investigating the development of innovative new generation CAR-T strategies effective against these malignancies and other tumors.